Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.
Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment ...
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Denali Therapeutics (DNLI) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for ...
In the wake of the debacle known as the Biden presidency, certain media commentators who supported Biden and looked the other ...
A viral outbreak in China sounds alarmingly familiar to 2019, back in the days before most of us had ever heard of the ...
Archaeologists in Switzerland have uncovered the ruins of a Roman-era amphitheater — possibly the youngest on record — where ...
Pacific Palisades resident Chris Reid, who was forced to evacuate his home, joins Chris Jansing to share his experience amid ...
Sen. Richard Blumenthal declared that the political battle is just starting after certification of President-elect Donald ...